CD44 and glioblastoma: Among the key genes identified, MYC, NOTCH1, TOP2A, CD44, PTPRC, SSRP1, CDK4, DKC1, HNRNPU, and PDGFRA have shown significant correlations with GBM prognosis and may serve as potential targets for therapeutic interventions.